Show Summary Details
Page of

Kidney disease 

Kidney disease
Kidney disease

Debasish Banerjee

, Robin Ramphul

, and David Goldsmith



Table 6.1.1 slightly revised

Additions made to the Primary percutaneous coronary intervention and Statins sections

Table 6.1.2 updated in line with new ESC Guidelines

Paragraph on Sodium–glucose co-transporter type 2 inhibitors included

Management of hypertension in chronic kidney disease section updated

Updated on 29 July 2020. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 28 November 2021

The cardiovascular disease profile in patients with chronic kidney disease, and liver disease and during pregnancy is different from that in the general population. Due to altered physiology in these conditions, drug handling is different. Hence, drug therapies in these conditions are described separately in this section. Cardiovascular disease is the commonest cause of morbidity and mortality in patients with chronic kidney disease. Yet drug therapy is often withheld or used in inappropriate doses. The kidneys have a major role in the pharmacokinetics of numerous drugs, and hence the renal function determines the dose and effect of these drugs. This chapter describes common cardiovascular events in chronic kidney disease patients and appropriate drug therapy. Evidence-based guidance is provided when appropriate, and the dose adjustments are as known, when available, in accordance to the current European Society of Cardiology guidelines.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.